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Background: Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The amyloid
precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid β
(Aβ) over-production, a major upstream pathway leading to Alzheimer disease (AD). Statins (microsomal
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), have pleiotropic effects including potentially increasing
brain amyloid clearance, making them plausible agents to reduce AD risk. Animal models, human observational studies,
and small scale trials support this rationale, however, there are no AD primary prevention trials in Down syndrome
adults. In this study we study aim to inform the design of a full-scale primary prevention trial.
Methods/Design: TOP-COG is a feasibility and pilot double-blind randomized controlled trial (RCT), with a nested
qualitative study, conducted in the general community. About 60 Down syndrome adults, aged ≥50 will be included.
The intervention is oral simvastatin 40mg at night for 12 months, versus placebo. The primary endpoint is recruitment
and retention rates. Secondary endpoints are (1) tolerability and safety; (2) detection of the most sensitive
neurocognitive instruments; (3) perceptions of Down syndrome adults and caregivers on whether to participate, and
assessment experiences; (4) distributions of cognitive decline, adaptive behavior, general health/quality of life, service
use, caregiver strain, and sample size implications; (5) whether Aβ42/Aβ40 is a cognitive decline biomarker. We will
describe percentages recruited from each source, the number of contacts to achieve this, plus recruitment rate by
general population size. We will calculate summary statistics with 90% confidence limits where appropriate, for each
study outcome as a whole, by treatment group and in relation to baseline age, cognitive function, cholesterol and
other characteristics. Changes over time will be summarized graphically. The sample size for a definitive RCT will be
estimated under alternative assumptions.
Discussion: This study is important, as AD is a major problem for Down syndrome adults, for whom there are
currently no effective preventions or treatments. It will also delineate the most suitable assessment instruments for
this population. Recruitment of intellectually disabled adults is notoriously difficult, and we shall provide valuable
information on this, informing future studies.
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Down syndrome and dementia
Adults with Down syndrome have a high prevalence of
dementia of Alzheimer disease (AD) type from middle
age onward [1,2]. Dementia is a highly disabling disorder
that results in progressive deterioration, increasing de-
pendency as well as health and social support resource
consumption and, ultimately, premature death. It has an
impact on adults with dementia and their family and
friends and also is a source of major societal and eco-
nomic costs. Down syndrome is the commonest cause of
early-onset dementia, with 40% of adults with Down
syndrome ages 50 years and older acquiring it [1,2]. Al-
most everyone with Down syndrome ages 40 and older
has neuropathological changes due to AD [3]. Because
the life expectancy of people with Down syndrome has
increased rapidly, with the majority now living beyond
50 years of age, preventive measures against AD are
urgently needed.
The amyloid precursor protein (APP) gene is located
on chromosome 21 and thus is overexpressed in Down
syndrome (trisomy 21), leading to amyloid β (Aβ) over-
production. Excess Aβ levels form insoluble plaques and
are a major upstream pathway leading to AD [4]. This is
thought to be the mechanism of action resulting in the
very high rates of AD in adults with Down syndrome.
The pathology of dementia in adults with Down syn-
drome differs from that in the general population. In the
general population vascular dementia and dementia in
AD often cannot be clinically differentiated. Indeed, an
increasing body of knowledge suggests that vascular
changes and AD pathology are interrelated [5,6]. In con-
trast, adults with Down syndrome develop a relatively
“pure” form of AD that supports the “amyloid hypothesis”
in the general population. This is so because people with
Down syndrome have a remarkable resilience to athero-
sclerosis [7,8], possibly due to the cystathionine β synthase
gene’s location on chromosome 21, which is overexpressed
in Down syndrome. This leads to decreased homocysteine
levels and thus reduced arteriosclerosis. As Down syn-
drome adults are atheroma-free [8], with low blood pres-
sure [8], and have low vascular dementia rates, their
dementia is a “pure” model of dementia in AD, unlike that
in the general population. In view of the specific genetic
differences in people with Down syndrome, the findings
produced by trials in the general population cannot be
extended to people with Down syndrome. There are
currently no effective interventions to prevent dementia
onset in routine clinical practice, but proof of concept has
been established in older adults with Down syndrome [9].
Evidence to date on a role for statins in Alzheimer disease
Normally, Aβ production is balanced by Aβ clearance via
apolipoprotein E (ApoE) receptors and the low-densitylipoprotein receptor (LDLR) [10]. LDL is bound by LDLR
and taken into the cell ending where it is degraded, and
cholesterol is made available for repression of microsomal
3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) re-
ductase, which is the rate-limiting step in cholesterol syn-
thesis. Statins are HMG CoA reductase inhibitors and thus
are plausible agents to use to reduce AD risk. Supporting
evidence has been produced by experimental studies, ob-
servations of populations, case-controlled observational
studies, prospective cohort studies, secondary prevention
trials and small-scale primary prevention trials with high-
risk groups, as described in the following paragraphs.
The brain has high levels of cholesterol. Cholesterol is
synthesized locally, and its elimination utilizes ApoE. Its
synthesis modulates the production of Aβ. Individuals
with the ApoE e4/4 allele are at particularly high risk for
developing AD in both the general population and the
population with Down syndrome, highlighting the role
of Aβ. In the general population without dementia,
ApoE e4 is associated with relative cognitive decline at
age 79 years [11], but healthier lipid profiles, such as
higher erythrocyte ω-3 polyunsaturated fatty acid con-
tent, are significant only in the absence of the ApoE e4
allele [12]. The hypothesized pathway link between lipid
metabolism and AD is amyloid clearance by the LDLR
family of proteins. Brain LDLR activity has been shown
to be increased significantly, especially in astrocytes,
by statin treatment [13]. The results of studies with
experimental animal models have demonstrated that
LDLR deficiency causes hypercholesterolemia, cerebral
β-amyloidosis and learning deficits [14] and that statins
improve learning and slow AD pathology development
[15]. LDLR-deficient Tg2576 mice develop hypercholes-
terolemia and age-dependent cerebral β-amyloidosis [14].
In the study by Cao et al. [14], LDLR-deficient Tg2576
mice showed more spatial learning deficits than LDLR-
intact Tg2576 mice did after the manifestation of Aβ
deposition. Although LDLR genotypes did not affect the
expression level of the Aβ precursor protein transgene,
there was a significant increase in Aβ deposition accom-
panied by an increase of APOE expression in LDLR-
deficient Tg2576 mice.
In humans, almost all the evidence to date is drawn
from the general population rather than from people
with Down syndrome. Rates of dementia in AD appear
to be low in populations with low blood cholesterol
levels and diets low in fat and cholesterol [16,17]. Some
study researchers have reported that high cholesterol
levels increase the risk of AD [18], although not all
found this to be so [19]. However, brain cholesterol is
synthesized locally, and it is unclear whether blood levels
are a suitable proxy measure.
Researchers in several case–control studies have re-
ported a lower risk of dementia among statin users than
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Cochrane review [27], the earlier studies were challenged
on indication bias. However, the finding in these studies
has been replicated, despite recent improvements in access
to health care for people with dementia.
In several prospective cohort studies, including recent
well-conducted, large-scale studies, investigators reported
that the use of statins predicted reduced incidence of AD
or was associated with trends toward slower cognitive de-
cline [26,28-33] or reduced risk of hospitalization due to
dementia [34]. The strength of association between statin
use and reduction in incidence of AD has been shown to
diminish with age [32]. Other study researchers have
reported no associations of statin use with AD [25,35], but
not all differentiated dementia in AD from vascular
dementias. Additionally, the amyloid pathway may not be
the major disease determinant in some cases. For example,
the religious order study participants had an exceptionally
high mean educational level of 18.2 years [36]. Also, as
amyloid pathway irregularities are upstream of dementia
development, the period of observation of statin treatment
may not cover all of the at-risk period. Researchers in one
study found that lifelong cognitive change data found
statins did indeed protect against cognitive decline in a
population at approximately 80 years age [37].
Only one study has been conducted on the use of sta-
tins in adults with Down syndrome. In it, the investiga-
tors studied the relationship between statin use and
incident dementia in AD over the course of 5 years in a
prospective US cohort of 123 participants ages 40 years
and older [9]. The participants on statins had less than
half the risk of incident dementia. In the same cohort,
persons with measurements of Aβ42 in the middle or
highest range were found to be more than twice as likely
to have incident dementia and persons with Aβ levels in
the highest third were more likely to die [38]. To the
best of our knowledge, to date, no trials of statins with
adults with Down syndrome have been reported and
none are currently registered.
With regard to trials involving the general population,
authors of a recent Cochrane review found only two
published statin RCTs for the primary prevention of
dementia [27]: the MRC/BHF Heart Protection Study
(HPS) [39] and the Prospective Study of Pravastatin in
the Elderly at Risk (PROSPER) study [40]. The HPS
investigators used brief telephone interviews to assess
cognition and found no effect of simvastatin 40 mg OD
versus placebo over the course of 5 years [39]. In the
PROSPER study, which was of older people, the trialists
did not report any benefits, on the basis of cognitive
testing, from pravastatin 40 mg OD therapy over a mean
course of 3.2 years [40]. However, their conclusions are
not relevant to adults with Down syndrome, as the study
participants were selected specifically for having vasculardisease and/or vascular risk factors and not for Aβ over-
production. Also, in neither trial did the investigators
study incident dementia in AD specifically, and cognitive
measures were only secondary outcomes. Indeed, the HPS
team did not collect baseline cognitive data, and good
baseline cognitive ability was required in the PROSPER
study (Mini Mental State Examination score >24). Re-
searchers in smaller studies including “AD high-risk
groups” have found benefits at 4 months and 6 months
[41,42]. The investigators in an AD high-risk study, the
European/Australasian Stroke Prevention in Reversible
Ischaemia Trial (ESPRIT) study, recruited 100 people
ages 35 to 69 years who had a parent with AD and stud-
ied simvastatin 80 mg OD. After 9 months, no difference
was found in change in cerebrospinal fluid (CSF) Aβ42,
although the degree of change was influenced by the
participant’s underlying risk profile [43].
In a small, secondary prevention randomized controlled
trial (RCT), the investigators randomized 63 people with
mild to moderate dementia in AD to atorvastatin 80 mg
once daily (OD) or placebo and demonstrated slowing in
cognitive decline in the statin group at 6 and 12 months
[44]. In a larger-scale, double-blind, placebo-controlled
study (the LEADe study), researchers recruited 640 partici-
pants with mild to moderate dementia and tested the
addition of atorvastatin 80 mg to treatment with a cholin-
esterase inhibitor. They found no difference in change in
cognition between the intervention and control groups
after 72 weeks [45]. Two large, placebo-controlled, second-
ary prevention trials are in progress: the statins/CLASP
(Collaborative Low-dose Aspirin Study in Pregnancy) study
(investigating simvastatin 40 mg) and the UCSD Statin
Study (investigating simvastatin 20 mg or pravastatin
40 mg). However, statins are theoretically more effective
in primary than in secondary prevention, so the results of
these studies will be less relevant to the study outlined in
this protocol. Authors of two more reviews recently
concluded that trials are indicated specifically when AD
is due to amyloid overproduction [46,47]. This is exactly
the situation in Down syndrome. Authors of a recent
systematic review of statins and cognitive function found
there is an absence of well-powered RCTs for most
cognitive outcomes and concluded that larger and better-
designed studies are needed [48].
Much of the literature on aging and dementia in the
general population does not apply to the atheroma-free
Down syndrome population. Given the exceedingly high
prevalence of dementia in AD in the Down syndrome
population, it is crucially important that trials with and
for them be undertaken.
Choice of statin and dose
There is no Down syndrome literature to inform the
choice of statin to investigate in a primary prevention
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to that in the general population. We therefore selected
simvastatin on theoretical rather than empirical grounds
for the following reasons:
1. Simvastatin is more lipophilic than hydrophilic
compared with other statins [49]; therefore, it
crosses the blood–brain barrier more easily and
hence is expected to be more effective than other
statins.
2. Simvastatin has a good safety record in the general
population. Researchers in clinical trials have
reported that myalgia occurred in 1.2% of
participants who received 40 mg OD [50]. They also
found no difference in muscle pain or weakness
between participants treated with simvastatin 40 mg
OD or placebo for 5 years or in the number who
discontinued treatment due to musculoskeletal
problems [39]. Adverse reactions increase at higher
doses [51]; hence we chose to use 40 mg OD in our
present study. The incidence of fatal rhabdomyolysis
has been estimated at 0.12% per 1 million prescriptions
on the basis of data derived from the US Food and
Drug Administration databases and the National
Prescription Audit Plus [50].
3. There is evidence derived from a general population
pilot RCT to support our choice of simvastatin
40 mg OD. After 26 weeks, participants with mild, but
not severe, dementia in AD taking simvastatin 80 mg
OD compared with placebo had statistically
significantly higher scores on the Mini Mental
State Examination and significantly decreased
CSF Aβ40 levels. The reduction was correlated
with CSF reduction in the cholesterol metabolite
24S-hydroxycholesterol. In participants with severe
dementia, the large proportion of Aβ deposited in
amyloid plaques may explain why a reduction
was not detected in CSF [52]. Additionally, 57
participants at high risk for AD showed improvements
in verbal fluency and on working memory measures
in a 4-month, double-blind RCT of simvastatin
40 mg OD [41].
Neuropsychological test instruments
High dementia incidence and caregiver-reported adap-
tive functional decline over time (that is, a proxy meas-
ure of decline) are well-reported in adults with Down
syndrome. Neuropsychological test materials used spe-
cifically to measure cognitive decline necessarily must
differ from the tests used with the general population, as
adults with Down syndrome have preexisting cognitive
deficits and therefore existing norms do not apply. Fur-
thermore, when assessing longitudinal decline, floor ef-
fects on general population measures prevent changebeing registered. Researchers have attempted to phenotype
the early stages and progression of dementia in the Down
syndrome population with adapted or specially devised
assessments [2,53-57]. Investigators in small-scale studies
have found a pattern of deterioration similar to that in
the general population, with memory problems being
the first clinical marker [53,54]. However, recently, study
researchers have suggested that deficits in executive
function, characterized by planning problems, personality
changes and development of problem behaviors, might
predate other aspects [2,57,58] and stem from the frontal
lobe problems associated with Down syndrome [2]. These
studies are limited by small sample sizes. Researchers in
several studies who have utilized a range of measures,
principally in the domains of memory, attention and ex-
ecutive function, have investigated cognitive decline with
aging in people with Down syndrome [53,56,59,60]. How-
ever, to the best of our knowledge, no longitudinal reports
of more than a handful of participants with Down syn-
drome ages 50 years and older have been published.
Although researchers who studied 322 adults with in-
tellectual disabilities published normative data derived
from the Neuropsychological Assessment of Dementia in
Intellectual Disabilities (NADIID), their investigation in-
cluded few people with Down syndrome 50 years of age
and older, and very sparse published longitudinal data on
cognitive decline in people in this age group [53].
We anticipate that performance on standardized tests
of cognitive function will be a more accurate and sensitive
measure of decline than caregiver-reported changes in
adaptive function. Hence, phenotyping is important. In this
study, we will delineate the instruments most sensitive for
detecting change by assessing the distribution of scores
cross-sectionally and over time in relation to age, baseline
scores and other participant characteristics. Hence the
results of this study will enable the development of a new
battery of tools comprising those with the greatest utility
for the early detection of decline. This is important in the
planning of a full-scale, primary prevention RCT.
Study aims
The aims of the study are (1) to acquire data to design a
full-scale multi-center RCT of simvastatin for the pri-
mary prevention of dementia in AD, (2) to test recruit-
ment and retention strategies to inform future trials
with this population, (3) to determine the best instru-
ments to use in future studies measuring cognitive de-
cline in adults with Down syndrome and (4) to investigate
mechanisms, using Aβ42/Aβ40 measurements as a puta-
tive surrogate biological marker. Additionally, consent will
be obtained for subsequent future longer-term follow-up
by record linkage to routinely collected health data and for
samples to be banked at the University of Glasgow for
potential future research.
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Type of study
The study is a double-blind RCT of 12 months of simva-
statin 40 mg OD by mouth versus placebo. It includes a
nested qualitative study. The flowchart shown in Figure 1
summarizes the study protocol.Identify adults with Down syndrome aged ≥50 in GG&C, Lothian, Tayside
Down Syndrome Scotland, local services, etc. and send inform
Telephone call with adults with Down syndrome aged ≥50/carers to answer
check whether they should be invited to participate*
N~100
Home visit to recruit, collect baseline data on cognitive function, adaptive be
Randomize, stratified by age (<55 years or ≥55 years), APO E e4, choleste
N=60
Simvastatin 40mg OD
N=30
Pla
N
Clinical and blood assessment for ARs
after 6-12 weeks of drug.
AEs assessed every 3 months
Clinical and blood
after 6-12 we
AEs assessed
Cognitive function and general health
assessed after 12 months of drug.
N~25
Cognitive functio
assessed after 12
N
Nested qualitative study
N~10,
plusN~10who are not RCTparticipants
Figure 1 Flowchart of the study protocol. AE, Adverse event; APO E, apolip
GG&C, NHS Greater Glasgow & Clyde; OD, Once daily; RCT, Randomized contr1. The study will be randomized to determine if, in this
population, participants and caregivers are willing to
receive the intervention or placebo without knowing
which is being administered. Randomization will be
stratified for baseline characteristics known to influence
cognitive decline (age <55 and ≥55 years and ApoE e4, via primary care,
ation
their questions and
Meets exclusion criteria*
Exclude
haviour and health.
rol (<5 or ≥5mmol/l)
cebo
=30
assessment for ARs
eks of placebo.
every 3 months
n and general health
months of placebo.
~25
*Exclusion criteria:
1) Failure to gain consent (2)
Unable to comply with the protocol
(3) Dementia at baseline (4)
Diabetes
(5) Atherosclerotic disease
(6) At risk of cardiovascular disease
(7) Liver disease
(8) Chronic renal insufficiency
(9) Prescribed: statin, fibrates;
nicotinic acid; cyclosporine, triazole
antifungals, including fluconazole,
itraconazole, posaconazole;
ketoconazole, voriconazole;
miconazole oral gel, macrolide
antibiotics, including erythromycin,
clarithromycin, telithromycin;
danazol; fusidic acid; HIV protease
inhibitors, e.g. nelfinavir;
nefazodone; verapami;
amiodarone; warfarin; diltiazem;
amlodipine; moderate CYP3A4
inhibitors if the person lives alone
or with only part-time paid
support;Hepatitis C protease
inhibitors, e.g. boceprivir, telaprivir.
(10) Previous statin SAR
(11) Unable or unwilling to avoid
consumption of grapefruit juice
(12) Alcohol use >21units/week for
men or >14 units/week for women.
oprotein E; AR, Adverse reaction; CYP3A4, Cytochrome P450 3A4;
olled trial; SAR, Serious adverse reaction.
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limited evidence of influence (cholesterol <5 mmol/L
and ≥5 mmol/L) to prevent any imbalance in
participant types between treatment groups.
2. Semistructured interviews will be conducted with
participant-caregiver dyads to gain an understanding
of their views on their decision whether to participate
and be randomized, and their assessment experiences.
Research questions
The research questions we will seek to answer are listed
below.
1. What are the trial recruitment and retention rates
and recruitment sources?
2. What are the rates of tolerability and safety of
simvastatin 40 mg OD?
3. Which instruments are the most sensitive for
detecting early cognitive decline with the least floor
effect in adults with Down syndrome adults?
4. What are the perceptions of adults with Down
syndrome and their caregivers regarding their
decision whether to participate and be randomized
and their assessment experiences?
5. What are the distributions of the primary outcome
measure (cognitive decline) and key secondary
outcome measures (adaptive behavior, general health
and quality of life, service use and caregiver strain)
that would be used in a definitive RCT, and what are
the sample size implications of these distributions?
6. Is Aβ42/Aβ40 a biomarker for cognitive decline?
7. Do the results support proceeding to a full RCT?
The outcome measures we will use to answer each of
the research questions listed above are described in the
subsections that follow.
Research question 1: feasibility
1. The numbers screened and recruited each month
over the course of the recruitment period
2. A measure of the retention of participants in the
study after 12 months
3. The percentage of the total number of participants
recruited from each source and the number of
contacts with each source to achieve this (The
source will be identified during the initial telephone
call to assess suitability of inviting the person to
participate. Each contact made will be recorded by
the researcher and Scottish Primary Care Research
Network staff documenting each contact on a
contact recording sheet.)
4. The number of participants recruited per base
general population size.Research question 2: tolerability and safety
1. Compliance will be assessed by counting returned
tablets every 3 months.
2. Blood will be taken to measure muscle enzyme
levels 6 to 12 weeks after starting the simvastatin or
placebo treatments.
3. Interviews will be conducted every 3 months, in
addition to recording spontaneously reported
adverse events (AEs) using the standard sponsor’s
AE standard operating procedure.
Research question 3: identification of the most suitable
cognitive measures
On the basis of published data regarding measures of
cognitive decline in people with Down syndrome, we have
identified eight tests considered most likely to be sensitive
to change. The tests are in the domains of memory, atten-
tion and executive function:
1. Memory for Objects from the NADIID battery [53]
2. Selective Attention Cancellation Task [60]
3. Pattern Recognition Memory from the Cambridge
Neuropsychological Test Automated Battery [61]
4. Cats and Dogs test [56]
5. Tower of London Test (a test of frontal lobe
executive function recently adapted for adults with
intellectual disabilities by our group) [62]
6. Cued Recall Test [63]
7. Category fluency [56]
8. Story recall (adapted from the Rivermead
Behavioural Memory Test for Children [64])
Scores at baseline and after 12 months of simvastatin
or placebo treatment will be compared for each of these
measures to identify which show the greatest degree of
change over the period and have the greatest utility across
the full range of intellectual disabilities.
Research question 4: participant/caregiver perceptions
Key themes will be identified from the semistructured
interviews in the nested qualitative study to improve our
understanding of participants’ perspectives about research
participation and randomization, and their assessment
experiences. The analysis will be guided by the framework
approach [65].
Research question 5: effect size
The measures described below will be used with the adults
with Down syndrome at baseline and after 12 months of
simvastatin or placebo treatment to determine the effect
size by comparing the simvastatin group with the placebo
group.
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cline (using the instruments outlined above) [53,60-64].
The secondary outcomes will be measured using the
following instruments:
1. American Association on Intellectual and
Developmental Disabilities Adaptive Behavior Scale
(to measure the adaptive function of persons with
intellectual disabilities) [66]
2. Townsend’s Disability Scale (to measure general
health) [67]
3. EQ-5D (the EuroQol 5-Dimension Questionnaire;
to measure health outcomes and quality of life)
(recently reviewed for use with people with intellectual
disabilities [68])
4. Client Service Receipt Inventory (to measure
demographics and extent of service use as well as
social changes, such as changes in level of paid
support, move to a nursing home or loss of day
placement) (This instrument was designed for use
with adults with intellectual disabilities and adults
with mental illness.) [69,70]
5. The 12-item General Health Questionnaire (to be
given to the caregivers at baseline and after 12
months to compare the health and carer strain of
caregivers of participants in the simvastatin group
with caregivers of participants in the placebo
group) [71].
Research question 6: biomarkers
At baseline and after 12 months of simvastatin or pla-
cebo treatment, blood will be taken to measure Aβ40/
Aβ42 levels for comparison between the simvastatin and
placebo groups.
Research question 7: recommendations for a full
randomized controlled trial
1. The size of the general population pool needed to
recruit adults with Down syndrome for the full RCT
will be determined on the basis of the rates of
recruitment and study completion in this pilot
study, combined with the treatment effect estimate
and uncertainty regarding the estimate. Additionally,
the sensitivity of the neuropsychological measures
will inform this decision, in particular with regard
to the floor effect with persons with the most
severe intellectual disabilities; in other words, to
provide information about the proportion of the
recruited population for whom it was possible to
detect and measure change and therefore the
likely proportion who would need to be excluded
based on their baseline assessment of intellectual
function.2. This pilot study will consider the size of the
geographical recruiting area required and hence
the associated costs. The full RCT would not be
appropriate if there were unexpected adverse
safety effects identified in this pilot study, which
we consider to be unlikely.
Ethical considerations and consent
The study was given a favorable opinion by the Scotland
A Research Ethics Committee (REC). In keeping with
this response, each potential participant’s capacity to
decide whether to participate in the trial will be assessed
through discussion of the study, which will be facilitated
with the person’s caregiver. This discussion with each
potential participant will include going through the in-
formation sheet, which will be designed for persons with
intellectual disabilities. The discussion will include what
their participation will involve and will inform them that
they will not benefit personally from taking part and that
they do not have to participate if they do not wish to.
Any questions that the person or caregiver has will be
discussed and answered. To assess the person’s ability to
understand, retain and weigh information about whether
to participate, the person with Down syndrome will be
asked to say what they think the study is about and what
it will involve if they take part. Individual informed con-
sent will then be obtained from persons who demonstrate
that they have a good grasp of the study and understand
that they can choose whether to take part. For persons
considered not to have full decision-making capacity to
consent to participate in the trial, the informed consent of
their legal representative, as defined in the Medicines for
Human Use (Clinical Trials) Regulations 2004 (CTR), will
be sought. A separate information sheet will be used with
relatives and other legal representatives for this purpose.
Participation in the qualitative component of the study
will require a separate consent. The legal requirement for
this in Scotland is to adhere to the Adults with Incapacity
(Scotland) Act, 2000. Hence, capacity to consent is as-
sessed as outlined above. Persons then consent for them-
selves if they have the decision-making capacity to do so;
otherwise, consent is obtained from their welfare guardian
or nearest relative (as defined in the Act).
Statistical power
Approximately 60 participants with Down syndrome
ages 50 and older will be randomized. Recruitment feasi-
bility will be assessed on the bases of the number of
people identified per 10,000 population and the percent-
ages of those contacted who would like to participate,
and, among those, the percentage who are eligible to
participate. For example, if 200 individuals are contacted
and 100 agree to be screened, from among whom 60 are
eligible for randomization, then the overall recruitment
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25% to 36%. This will be sufficiently accurate to allow
planning for a larger RCT. Similarly, if 50 participants
complete the 12-month follow-up, the retention rate will
be 83% with a 90% CI of 73% to 91%.
The variance of the rate of cognitive decline will be
estimated to calculate the sample size required for a
definitive RCT. The precision of this estimate is a func-
tion of the sample size in this pilot study. We think
that a sample size of 50 participants from whom we
gather 12-month outcome data is appropriate at this
stage to provide a variance estimate that is reasonably
precise, without requiring that we recruit an excessively
large sample. With 50 participants, a 90% CI for the
variance in the rate of cognitive decline will have a
width of approximately 70% of the estimated variance.
A smaller sample size in this pilot study would greatly
increase the uncertainty in the variance estimate, whereas
calculation of a more precise estimate could require
considerably more participants. For example, halving
the width of the 90% CI for the estimated variance
would require 180 participants, which we believe is too
large for a pilot study designed to show the feasibility
of an RCT.
Sample size for the qualitative study
We do not know in advance how many interviews will
be necessary to reach saturation (with no new themes
emerging), but we will plan to interview ten dyads of
participants with Down syndrome and their caregivers
and will also attempt to recruit ten dyads of adults
with Down syndrome and their caregivers who choose
not to participate in the pilot RCT. It is possible that
some dyads will agree to this single, semistructured
interview despite having declined to participate in the
pilot RCT.
Participants and their recruitment
For the RCT, we will recruit approximately 60 adults
with Down syndrome ages 50 and older. Potential partic-
ipants will be given or sent information packs and in-
vited to reply to the research team if they are interested
in further information about participating.
Although all older adults with Down syndrome will
be known to their primary care teams, it is likely
that a more efficient recruitment strategy will com-
bine primary care, registry-based and wider recruitment
methods, with snow-balling. We will test recruitment
using a multipronged approach in Greater Glasgow
and Clyde, Lothian and Tayside utilizing the following
resources:
1. Scottish Primary Care Research Network
2. Scottish Dementia Clinical Research Network3. Down Syndrome Scotland membership list
4. Scottish Consortium for Learning Disabilities and
their e-SAY project
5. Professionals working within specialist intellectual
disabilities health and social work services
6. Larger provider organizations of 24-hour support
packages and specialist day care
If the recruitment rate is lower than anticipated within
the first 2 months of recruitment initiation, then ap-
provals will be sought to expand recruitment efforts into
other areas of Scotland utilizing the same methods. If
interest to participate in the study is high, we will recruit
the first 60 suitable participants while continuing to
measure the response rate. To judge the most effective
means of recruitment, during the screening call to gauge
each individual’s eligibility to participate in the study, we
will inquire if the person knows the source of the infor-
mation pack they received which resulted in their reply-
ing for more information about the study.
Two groups of participants will be selected for the quali-
tative study. They will be drawn from among (1) those
who participated in the RCT and (2) those who de-
clined to participate in the RCT or did not respond to
the invitation to participate. For the first group, we will
try to avoid bias by purposively sampling ten partici-
pants and their caregivers (including people across the
range of ability levels of intellectual disabilities and paid
and family caregivers) who had baseline assessments
during the first 3 months of recruitment (maximum
variance sampling). For the second group, we will also
attempt to recruit ten Down syndrome and caregiver
dyads who did not take up the invitation to participate
in the pilot RCT. We will attempt to recruit people
with family caregivers, people with paid caregivers and
people across the range of ability levels of people with
intellectual disabilities, but we acknowledge that there
may in limitations in how successful we will be with
this second group.
Inclusion and exclusion criteria
The inclusion criteria are (1) a diagnosis of Down syn-
drome and (2) age 50 years or older. The exclusion
criteria are listed below:
1. No consent obtained
2. Unable to comply with the protocol, including
providing blood or saliva for baseline ApoE e4
measurement and venous or capillary blood for
cholesterol measurement
3. Dementia at baseline (as the study is investigating
primary prevention)
4. Diabetes (as this is an indication for prescription
of a statin)
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an indication for prescription of a statin)
6. Being at risk for cardiovascular disease (as this is an
indication for prescription of a statin)
7. Liver disease
8. Chronic renal insufficiency
9. Currently being prescribed any of the following:
a. A statin
b. Fibrates
c. Nicotinic acid
d. Cyclosporine
e. Triazole antifungals, including fluconazole,
itraconazole, posaconazole, ketoconazole,
voriconazole, miconazole oral gel, verapamil)
f. Macrolide antibiotics (including erythromycin,
clarithromycin, telithromycin)
g. Danazol
h. Fusidic acid
i. HIV protease inhibitors (for example, nelfinavir,
nefazodone, verapamil, amiodarone, warfarin,
diltiazem, amlodipine)
j. Moderate CYP3A4 inhibitors (if the person lives
alone or has only part-time paid support)
k. Hepatitis C protease inhibitors (for example,
boceprevir, telaprevir)
10. Previous serious adverse reaction to a statin
11. Unable or unwilling to avoid consumption of
grapefruit juice
12. Excessive alcohol use (defined as >21 U/wk for men
and >14 U/wk for women)
Group allocation and blinding
Participants will be randomly assigned to either simva-
statin or placebo and stratified by age, ApoE e4 allele
and cholesterol level. After collecting baseline data
and samples, the researcher will notify the Robertson
Centre for Biostatistics (RCB) of the participant’s study
number and age via the web portal. The laboratory
will notify the RCB of the participant’s ApoE status
and cholesterol level, also via the web portal. The RCB
will then notify the pharmacy of group allocation and
generate an email to the research assistant notifying
him or her that randomization has taken place as well
as of the medication pack number assigned. The phar-
macy will then dispense the medication. A verifiable
audit trail will be ensured. The research assistant will
telephone participants to check whether the medica-
tion has arrived and instructions are fully understood.
The research team will therefore remain blinded to
both ApoE and group allocation status, as will the
participants and their caregivers. Medications will be
dispensed within 4 weeks of baseline data collection.
This time frame will allow for batching of the ApoE
analyses.Duration of participation
Participation
Each participant’s participation in the study will last
for 12 months postrandomization unless they withdraw
prematurely.
Completion
The date of completion for safety is defined as the last
dose of simvastatin or placebo plus 30 days. For other
study outcomes, each participant will be considered to
have completed the study either after the completion of
the last assessment visit or after receiving the last dose
of simvastatin or placebo, whichever is later. The date of
discontinuation will be recorded as the date on which a
participant and/or investigator determines that the par-
ticipant can no longer comply with the requirements for
any further study visits or assessments.
Assessments
Assessments and blood tests will be conducted either
in the person’s own home or at another venue if the
participant/caregiver prefers. Home visits will be offered
in order to increase recruitment and retention and for
the convenience of the participants and caregivers, as
well as to conduct the psychometric tests as accurately
as possible by conducting them in a familiar, comfortable
environment for the participant.
Intervention
The intervention is simvastatin 40 mg at night by oral
administration. The simvastatin will be overencapsulated.
The control group will receive an oral placebo capsule at
night by mouth. The capsules are to be swallowed whole,
not chewed. Dose modifications are not allowed. A sum-
mary of product characteristics is available, as is an Investi-
gational Medicinal Product Dossier. The drug and placebo
will be prepared by the Pharmacy Production Unit based
at the Western Infirmary in Glasgow.
Unblinding procedure
Unblinding will be permitted in emergencies where,
for medical or safety reasons, it is necessary to know
which treatment a participant has received. Study par-
ticipants will be provided with a Participant Alert Card
that will include the name of the investigational study
drug, their study number, the investigator’s name and
a 24-hour telephone number for unblinding purposes.
Unblinding will be done via a telephone menu system.
Several prompts in the system will warn the user that
he or she is required to be a health professional and
that name and other pertinent information must be re-
corded. At each unblinding, an email alert to the Chief
Investigator will be generated. Requests will be set at a
maximum of two per 24 hours to prevent malicious
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from participants at the end of their involvement in the
study.
Expected adverse reactions
The expected adverse reactions are listed below. There is
no theoretical reason to expect a higher rate in adults with
Down syndrome.
1. Myalgia
2. Myositis
3. Rhabdomyolysis
4. Flulike symptoms
5. Fatigue
6. Headache
7. Nausea
8. Diarrhea
9. Fatal and nonfatal hepatic failure
10. Raised HbA1c and fasting glucose
11. Diabetes mellitus
12. Cognitive impairment (rarely)
Definitions of muscular adverse reactions
1. Alanine aminotransferase and aspartate
aminotransferase elevation will be defined as more
than three times the upper limit of normal.
2. Myalgia is defined as muscle ache or weakness
without creatine kinase (CK) elevation.
3. Myositis is defined as muscular symptoms with a
CK level more than ten times the upper limit of
normal.
4. Rhabdomyolysis is defined as a CK level >10,000 U/L
with or without muscular symptoms.
All AEs and intercurrent illnesses will be recorded,
notified, reported, analyzed and managed in accordance
with the CTR. The research sponsor’s standard operating
procedures for recording and reporting AEs and serious
AEs will be followed. An annual safety report will be sub-
mitted to the Medicine and Healthcare Products Regula-
tory Agency and the REC within 60 days of the anniversary
of the issue of the clinical trial’s authorization. Safety
data will be measured through three monthly telephone
interviews.
Data analysis
Recruitment
During the initial phone call, we will identify the source
to which the person responded. We will describe the
percentage of the total recruited from each source and
the number of contacts with each source required to
achieve this total (via diary records). We will also calcu-
late recruitment by base general population size.Pilot randomized controlled trial
A detailed statistical analysis plan will be prepared prior
to the unblinding to treatment allocations, according to
the RCB/Glasgow Clinical Trials Unit standard operating
procedures. Briefly, summary statistics will be presented,
with 90% confidence limits where appropriate, for each
study outcome as a whole, by treatment group and in re-
lation to baseline participant characteristics. Changes in
outcomes over time will be summarized and presented
graphically. The treatment effect estimate is of interest,
not so much in terms of the magnitude or statistical sig-
nificance of effect (the sample size is too small to draw
definitive conclusions in this study), but rather regarding
the uncertainty in this estimate or the variability in the
rate of cognitive decline from which this estimate is
derived. It is this variability estimate that will inform the
sample size for a definitive trial, along with information
about likely recruitment and retention rates. Statistical
results will be interpreted in terms of the implications
for a definitive RCT; for example, the sample size (and
cost) required for screening and randomization will be
estimated under alternative assumptions based on the
pilot data. In additional analyses, we will examine
outcomes of cognitive decline in relation to age, ApoE
status, baseline cognitive function, cholesterol level and
other baseline characteristics, which may provide infor-
mation useful in defining the target population in future
studies. We intend to apply exploratory factor analysis
and other data reduction methods to examine interrela-
tionships between different cognitive measures and their
changes over time. The data gathered will not be suffi-
cient to propose alternative outcome measures based on
this analysis, but we may be able to propose novel
hypotheses to be tested in a larger study.
Qualitative study
Topic guides will be used in the semistructured inter-
views, but they will be flexible. They will focus on the
issues that potential study participants consider when
deciding whether to take part in the study and, after the
study, what made taking part a positive or negative ex-
perience for them. The interviews will be tape-recorded
and transcribed verbatim. The analysis will be guided by
the framework approach [63]. As such, the analytic
process will be deductive in that it will be guided by the
aims of the study, but it will simultaneously be inductive
and flexible and thereby allow key themes to emerge.
The tape-recorded interviews will be transcribed as close
to the time of the interview as possible, and the re-
searcher’s field notes will be checked to ensure accurate
transcription. Analysis will begin during the interview
period so that any themes which arise can be verified in
later interviews. The researcher will review the tran-
scripts to identify the key issues of importance for
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be analyzed independently by a second member of the
research team who is blinded to the themes identified by
the researcher to ensure consistency of identification of
themes and that the identified themes are an accurate
reflection of the material. The results will be fed back to
the participant-caregiver dyads to find out if they concur
with our findings. The themes will be used to make
suggestions about how to revise and/or improve the
study processes for participants.
Discussion
We think this study is important, as dementia is such
a major problem for adults with Down syndrome. At
present, there are no interventions that have been found
to be effective for them in either preventing dementia or
treating it. This feasibility/pilot study is the first step to-
ward informing a large-scale RCT to determine whether
simvastatin is effective in preventing or delaying the on-
set of dementia in this group. Additionally, the findings
are likely to be relevant to clinical practice as well as to
future research because, at present, there is no neuro-
psychological test battery accepted as best practice for
use with adults with Down syndrome. This study will
provide information on the instruments that may be
useful in this regard. In view of the age range of the par-
ticipants (50 years and over), the study should be more
informative about neuropsychological test instruments
than previous work with younger adults with Down
syndrome. The study will allow us to determine whether
our battery of cognitive tests is sensitive to cognitive
decline over a 1-year period in the placebo group.
Recruitment is often a challenge in general population
trials [72]. The authors of a Cochrane review on strat-
egies to improve recruitment concluded that (1) trialists
should include evaluations of their recruitment strategies
and (2) funders should support these evaluations be-
cause the number of interventions that have been rigor-
ously evaluated in the context of a real trial is low [73].
Recruitment of adults with intellectual disabilities is
notoriously difficult. They are routinely excluded from
general population medication trials, and very few trials
have been designed specifically for them. There are
challenges in conducting research with this group, and
recruitment may be atypical [74,75]. In an antipsychotic
drug study of adults with intellectual disabilities with
aggressive behaviors, the investigators had substantial
recruitment problems but excellent retention rates. Only
72% of the intended participant numbers were recruited,
despite an increase in recruitment time from 2 to 4 years
and an extension of study sites [75]. Previous studies of
rivastigmine and donepezil with adults with Down syn-
drome were small in scale and of short duration and the
participants recruited were adults younger than proposedin our protocol; hence they were less challenging to recruit
than in our study because of the larger pool of potential
participants for those studies [76,77]. As the participants in
the previous studies cited already had dementia, the motiv-
ation of the participants and their caregivers might con-
ceivably differ from that of the potential participants in our
study, who will be disease-free. In a larger study of meman-
tine, participants were recruited over a 2.5-year period in
England and Norway. They included adults at the younger
age of 40 years and people who did and did not have
dementia; hence recruitment was less challenging than in
our study [78]. The likely recruitment and retention rates
with this population in the age range chosen for our study
are unknown and might be atypical. There is not a body
of research to understand the choices made by older per-
sons with Down syndrome and their caregivers regarding
research, as well as what motivates them whether to par-
ticipate, their perceptions regarding randomization and
their experiences in the studies. Concerns about what
randomization is and what then happens to participants
may be significant blocks to recruitment; hence an im-
portant part of this study is to better understand these
perceptions with a view toward minimizing them in
future studies. These knowledge gaps will be addressed in
this study, which should provide valuable information on
recruitment and retention to inform future studies.
Trial status
We will complete recruitment in June 2014.
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